Clinical trials: Lung Metastasis
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer
Study of XB010 in Subjects With Solid Tumors
This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic…
- Conditions
- Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- NCT06545331
- Testing
- XB010, Pembrolizumab
- Where
- 20 sites in United States, United Kingdom
- Volunteers
- 396 people
- Sponsor
- Exelixis
Thyroid Pathology, Head and Neck Cancer (H&N)
FAPI PET Imaging - An Exploratory Study
This study is testing a new imaging tracer called [18F]FAPI-74 with PET scans. Researchers want to find out how well this tracer shows certain diseases in the body, including several types of cancer and some non-cancer conditions…
- Conditions
- Thyroid Pathology, Head and Neck Cancer (H&N), Sinonasal Tract Tumor, Sarcoidosis
- Trial name
- FAPIPET (NCT07705074)
- Testing
- [18F]FAPI-74 PET/CT
- Where
- 5 sites in Switzerland
- Volunteers
- 770 people
- Sponsor
- Martin Huellner
Non-small Cell Lung Cancer, Adenocarcinoma
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment
A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment
- Conditions
- Non-small Cell Lung Cancer, Adenocarcinoma, Stage IV
- Trial name
- NCT04263090
- Testing
- Rigosertib, Nivolumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Breast Carcinoma, Locally Advanced Breast Cancer
Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients
Study objective: Cohort 1: To quantify the uptake of 68GaNOTA-Anti-HER2 VHH1 in local or distant metastases from breast carcinoma patients and to assess repeatability of the image-based HER2 quantification.
- Conditions
- Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas, Solid Tumor With Intermediate or High HER2 Expression
- Trial name
- VUBAR (NCT03924466)
- Testing
- 68GaNOTA-Anti-HER2 VHH1
- Where
- Belgium
- Volunteers
- 55 people
- Sponsor
- Universitair Ziekenhuis Brussel
Non-small Cell Lung Cancer Metastatic
A Study of LY3023414 and Necitumumab in Squamous Lung Cancer
The main purpose of this study is to evaluate the safety and activity of the study drug known as LY3023414 in combination with necitumumab in participants with metastatic squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT02443337
- Testing
- LY3023414, Necitumumab
- Where
- 14 sites in United States
- Volunteers
- 31 people
- Sponsor
- Eli Lilly and Company
Non Small Cell Lung Cancer
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
The purpose of the study is to evaluate safety, pharmacokinetics and efficacy of AB-106 monotherapy in the treatment of advanced NSCLC.
- Trial name
- NCT04395677
- Testing
- AB-106
- Where
- China
- Volunteers
- 173 people
- Sponsor
- Nuvation Bio Inc.
Non Small Cell Lung Cancer
Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases
'1. Objective Primary objective Median Intracranial Progression-free survival(icPFS) as defined by RANO(Response Assessment in Neuro-Oncology) criteria Secondary objective Progression free survival(PFS) as defined by RECIST 1.1…
- Trial name
- ELPIS (NCT06250777)
- Testing
- Trastuzumab deruxtecan
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Yonsei University
Carcinoma, Non-Small-Cell Lung
Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to test whether SU011248 has activity and is safe in patients with metastatic non-small cell lung cancer (NSCLC) who have failed a platinum-containing regimen and docetaxel.
- Trial name
- NCT00092001
- Testing
- Sunitinib
- Where
- 14 sites in United States, Italy and 1 more
- Volunteers
- 111 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X…
- Trial name
- NCT05168566
- Testing
- Sutetinib Maleate Capsule
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 128 people
- Sponsor
- Teligene US
Non-small Cell Lung Cancer, Lung Cancer
ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer
This large phase III clinical study is studying the effect of vandetanib (ZACTIMA) in treating non-small cell lung cancer (NSCLC).
- Trial name
- ZODIAC (NCT00312377)
- Testing
- Docetaxel, Vandetanib
- Where
- 156 sites in United States, Argentina and 23 more
- Volunteers
- 1,690 people
- Sponsor
- Genzyme, a Sanofi Company
Metastatic ALK+ Non Small Cell Lung Cancer
Post Marketing Surveillance(PMS) Study of Lorviqua in Korea
The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua
- Trial name
- NCT05599412
- Testing
- Lorviqua
- Where
- South Korea
- Volunteers
- 600 people
- Sponsor
- Pfizer
Metastatic Squamous Non-Small Cell Lung Cancer, Metastatic Nonsquamous Non-Small Cell Lung Cancer
Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer
The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metastatic squamous and nonsquamous non-small cell lung cancer (NSCLC).
- Trial name
- POD1UM-304 (NCT04205812)
- Testing
- Retifanlimab, Pemetrexed, Cisplatin
- Where
- 140 sites in United States, Brazil and 15 more
- Volunteers
- 583 people
- Sponsor
- Incyte Corporation
Sarcomatoid Carcinoma of Lung
Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma
This is a single arm, multi-center clinical trial. Target population is patients with Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma，aiming to evaluate the efficacy and safety of the combination therapy of Camrelizumab…
- Trial name
- CAPSTONE (NCT04888429)
- Testing
- Camrelizumab, Famitinib
- Where
- 8 sites in China
- Volunteers
- 17 people
- Sponsor
- Qian Chu
Non Small Cell Lung Cancer
Erlotinib as 1st Line Treatment in NSCLC Stage IIIB/IV
To evaluate the efficacy and toxicity of erlotinib as first line treatment in patients with locally advanced/metastatic (stages IIIB/IV) NSCLC, with clinical predictors of response to tyrosine kinase inhibitors (erlotinib…
- Trial name
- NCT00615758
- Testing
- Erlotinib
- Where
- 5 sites in Greece
- Volunteers
- 50 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer, Lung Cancer
Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00059943
- Testing
- docetaxel
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC
LUNG-05: Investigating Chemotherapy Effectiveness for Non-Small Cell Lung Cancer (NSCLC) Metastatic Patients
This is a Single arm, Simon's two stage pilot study in which patients with Non-Small Cell Lung Cancer (NSCLC) with metastatic disease 2L and beyond will receive OncoChoice-informed chemotherapy following National Cancer Care…
- Trial name
- LUNG-05 (NCT06576635)
- Testing
- Docetaxel, Paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- University of Illinois Chicago
Non-Small Cell Lung Cancer
EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC
This is a multi-center phase III randomized controlled study, designing to access whether the efficacy of EGFR-TKI alone on patients with brain metastasis from non-small cell lung cancer (NSCLC) harboring EGFR mutant type is not…
- Trial name
- NCT02714010
- Testing
- EGFR-TKI, whole brain radiotherapy
- Where
- China
- Volunteers
- 601 people
- Sponsor
- Sun Yat-sen University
Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects
Evaluate the safety, tolerability, and objective response rate (ORR) of SHR2554 tablets in combination with other anti-tumor treatments in subjects with locally advanced or metastatic non-small cell lung cancer
- Trial name
- NCT07175220
- Testing
- SHR2554; SHR-A2102, SHR2554; Adabelimumab, SHR2554; SHR-1701
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
COPD
Real-World Treatment Patterns and Patient Reported Outcome in COPD (REMIND)
This retrospective observational study aims to report distribution of the proportion of symptomatic Chronic obstructive pulmonary disease (COPD) patients classified by the COPD Assessment Test (CAT) managed with single or dual…
- Trial name
- REMIND (NCT05903989)
- Where
- Japan
- Volunteers
- 708 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.